Table 7.
Treatment emergent adverse events
| Adverse events | TACE + lenvatinib (n = 60) |
TACE (n = 60) |
||
|---|---|---|---|---|
| All grades n (%) |
Grade 3/4 n (%) |
All grades n (%) |
Grade 3/4 n (%) |
|
| Decreased albumin | 33 (55.0%) | 0 (0.0%) | 23 (38.3%) | 0 (0.0%) |
| Hypertension | 29 (48.3%) | 14 (23.3%) | 0 (0.0%) | 0 (0.0%) |
| Decreased PLT | 28 (46.7%) | 8 (13.3%) | 30 (50.0%) | 5 (8.3%) |
| Elevated AST | 23 (38.3%) | 2 (3.3%) | 20 (33.3%) | 0 (0.0%) |
| Elevated GGT | 17 (28.3%) | 1 (1.7%) | 22 (36.7%) | 4 (6.7%) |
| Decreased WBC | 17 (28.3%) | 2 (3.3%) | 13 (21.7%) | 3 (5.0%) |
| Elevated ALT | 14 (23.3%) | 1 (1.7%) | 11 (18.3%) | 0 (0.0%) |
| Bleeding (gingiva) | 13 (21.7%) | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) |
| Elevated TB | 11 (18.3%) | 1 (1.7%) | 15 (25.0%) | 0 (0.0%) |
| Diarrhea | 11 (18.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Fatigue | 10 (16.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Dysphonia | 9 (15.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Hand-foot skin reaction | 7 (11.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Elevated creatinine | 2 (3.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Prolonged PT | 2 (3.3%) | 0 (0.0%) | 5 (8.3%) | 0 (0.0%) |
| Albuminuria/Proteinuria | 2 (3.3%) | 2 (3.3%) | 0 (0.0%) | 0 (0.0%) |
| Decreased appetite | 2 (3.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Joint pain | 2 (3.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Edema | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Constipation | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
TACE transcatheter arterial chemoembolization, PLT platelet, AST aspartate transaminase, GGT γ-glutamyl transpeptidase, WBC white blood cell, ALT alanine aminotransferase, TB total bilirubin, PT prothrombin time